Literature DB >> 33625214

Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta.

Nan Bai1,2, Sven A Miller1, Grigorii V Andrianov1,3, Max Yates1, Palani Kirubakaran1, John Karanicolas1.   

Abstract

Proteolysis-targeting chimaeras (PROTACs) are molecules that combine a target-binding warhead with an E3 ligase-recruiting moiety; by drawing the target protein into a ternary complex with the E3 ligase, PROTACs induce target protein degradation. While PROTACs hold exciting potential as chemical probes and as therapeutic agents, development of a PROTAC typically requires synthesis of numerous analogs to thoroughly explore variations on the chemical linker; without extensive trial and error, it is unclear how to link the two protein-recruiting moieties to promote formation of a productive ternary complex. Here, we describe a structure-based computational method for evaluating the suitability of a given linker for ternary complex formation. Our method uses Rosetta to dock the protein components and then builds the PROTAC from its component fragments into each binding mode; complete models of the ternary complex are then refined. We apply this approach to retrospectively evaluate multiple PROTACs from the literature, spanning diverse target proteins. We find that modeling ternary complex formation is sufficient to explain both activity and selectivity reported for these PROTACs, implying that other cellular factors are not key determinants of activity in these cases. We further find that interpreting PROTAC activity is best approached using an ensemble of structures of the ternary complex rather than a single static conformation and that members of a structurally conserved protein family can be recruited by the same PROTAC through vastly different binding modes. To encourage adoption of these methods and promote further analyses, we disseminate both the computational methods and the models of ternary complexes.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33625214      PMCID: PMC8866032          DOI: 10.1021/acs.jcim.0c01451

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  82 in total

1.  Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.

Authors:  A Rodriguez-Gonzalez; K Cyrus; M Salcius; K Kim; C M Crews; R J Deshaies; K M Sakamoto
Journal:  Oncogene       Date:  2008-09-15       Impact factor: 9.867

Review 2.  Viral modulators of cullin RING ubiquitin ligases: culling the host defense.

Authors:  Michele Barry; Klaus Früh
Journal:  Sci STKE       Date:  2006-05-16

3.  Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC).

Authors:  Chung Hyo Kang; Dong Ho Lee; Chong Ock Lee; Jae Du Ha; Chi Hoon Park; Jong Yeon Hwang
Journal:  Biochem Biophys Res Commun       Date:  2018-09-28       Impact factor: 3.575

4.  Delineating the role of cooperativity in the design of potent PROTACs for BTK.

Authors:  Adelajda Zorba; Chuong Nguyen; Yingrong Xu; Jeremy Starr; Kris Borzilleri; James Smith; Hongyao Zhu; Kathleen A Farley; WeiDong Ding; James Schiemer; Xidong Feng; Jeanne S Chang; Daniel P Uccello; Jennifer A Young; Carmen N Garcia-Irrizary; Lara Czabaniuk; Brandon Schuff; Robert Oliver; Justin Montgomery; Matthew M Hayward; Jotham Coe; Jinshan Chen; Mark Niosi; Suman Luthra; Jaymin C Shah; Ayman El-Kattan; Xiayang Qiu; Graham M West; Mark C Noe; Veerabahu Shanmugasundaram; Adam M Gilbert; Matthew F Brown; Matthew F Calabrese
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-16       Impact factor: 11.205

5.  Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation.

Authors:  Kathleen M Sakamoto; Kyung B Kim; Rati Verma; Andy Ransick; Bernd Stein; Craig M Crews; Raymond J Deshaies
Journal:  Mol Cell Proteomics       Date:  2003-10-02       Impact factor: 5.911

6.  p63 is a cereblon substrate involved in thalidomide teratogenicity.

Authors:  Tomoko Asatsuma-Okumura; Hideki Ando; Marco De Simone; Junichi Yamamoto; Tomomi Sato; Nobuyuki Shimizu; Kazuhide Asakawa; Yuki Yamaguchi; Takumi Ito; Luisa Guerrini; Hiroshi Handa
Journal:  Nat Chem Biol       Date:  2019-10-07       Impact factor: 15.040

7.  Open Babel: An open chemical toolbox.

Authors:  Noel M O'Boyle; Michael Banck; Craig A James; Chris Morley; Tim Vandermeersch; Geoffrey R Hutchison
Journal:  J Cheminform       Date:  2011-10-07       Impact factor: 5.514

8.  Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.

Authors:  Eric S Fischer; Kerstin Böhm; John R Lydeard; Haidi Yang; Michael B Stadler; Simone Cavadini; Jane Nagel; Fabrizio Serluca; Vincent Acker; Gondichatnahalli M Lingaraju; Ritesh B Tichkule; Michael Schebesta; William C Forrester; Markus Schirle; Ulrich Hassiepen; Johannes Ottl; Marc Hild; Rohan E J Beckwith; J Wade Harper; Jeremy L Jenkins; Nicolas H Thomä
Journal:  Nature       Date:  2014-07-16       Impact factor: 49.962

9.  ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules.

Authors:  Haim Ashkenazy; Shiran Abadi; Eric Martz; Ofer Chay; Itay Mayrose; Tal Pupko; Nir Ben-Tal
Journal:  Nucleic Acids Res       Date:  2016-05-10       Impact factor: 16.971

10.  Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities.

Authors:  Carles Galdeano; Morgan S Gadd; Pedro Soares; Salvatore Scaffidi; Inge Van Molle; Ipek Birced; Sarah Hewitt; David M Dias; Alessio Ciulli
Journal:  J Med Chem       Date:  2014-10-06       Impact factor: 7.446

View more
  7 in total

Review 1.  Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs.

Authors:  Ruth Nussinov; Mingzhen Zhang; Ryan Maloney; Yonglan Liu; Chung-Jung Tsai; Hyunbum Jang
Journal:  J Mol Biol       Date:  2022-04-01       Impact factor: 6.151

2.  Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity.

Authors:  Victoria G Klein; Adam G Bond; Conner Craigon; R Scott Lokey; Alessio Ciulli
Journal:  J Med Chem       Date:  2021-12-09       Impact factor: 7.446

Review 3.  Current strategies for the design of PROTAC linkers: a critical review.

Authors:  Robert I Troup; Charlene Fallan; Matthias G J Baud
Journal:  Explor Target Antitumor Ther       Date:  2020-10-30

Review 4.  Proteolysis Targeting Chimeric Molecules: Tuning Molecular Strategies for a Clinically Sound Listening.

Authors:  Federica Pedrucci; Claudia Pappalardo; Giovanni Marzaro; Nicola Ferri; Alberto Ferlin; Luca De Toni
Journal:  Int J Mol Sci       Date:  2022-06-14       Impact factor: 6.208

5.  Predicting the structural basis of targeted protein degradation by integrating molecular dynamics simulations with structural mass spectrometry.

Authors:  Tom Dixon; Derek MacPherson; Barmak Mostofian; Taras Dauzhenka; Samuel Lotz; Dwight McGee; Sharon Shechter; Utsab R Shrestha; Rafal Wiewiora; Zachary A McDargh; Fen Pei; Rajat Pal; João V Ribeiro; Tanner Wilkerson; Vipin Sachdeva; Ning Gao; Shourya Jain; Samuel Sparks; Yunxing Li; Alexander Vinitsky; Xin Zhang; Asghar M Razavi; István Kolossváry; Jason Imbriglio; Artem Evdokimov; Louise Bergeron; Wenchang Zhou; Jagat Adhikari; Benjamin Ruprecht; Alex Dickson; Huafeng Xu; Woody Sherman; Jesus A Izaguirre
Journal:  Nat Commun       Date:  2022-10-06       Impact factor: 17.694

6.  Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo.

Authors:  Guoshun Luo; Zhenbang Li; Xin Lin; Xinyu Li; Yu Chen; Kun Xi; Maoxu Xiao; Hanlin Wei; Lizhe Zhu; Hua Xiang
Journal:  Acta Pharm Sin B       Date:  2020-11-06       Impact factor: 11.413

Review 7.  Unifying Catalysis Framework to Dissect Proteasomal Degradation Paradigms.

Authors:  Frances P Rodriguez-Rivera; Samuel M Levi
Journal:  ACS Cent Sci       Date:  2021-06-16       Impact factor: 14.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.